| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers G > Headlines for Gedeon Richter, Ltd. > News item |
KV to market generic drugs in U.S. through deal with Gedeon
By Lisa Kerner
Erie, Pa., Feb. 14 - KV Pharmaceutical Co. and Gedeon Richter, Ltd. said that KV has acquired exclusive rights from Gedeon to market a broad group of generic drug products in the U.S. marketplace through KV's wholly-owned generic marketing division, Ethex Corp.
The products are for the cardiovascular, diabetic and central nervous system markets, including psychotropic categories, according to a company news release.
Based on 2005 IMS data, the estimated branded annual sales volume value of the products is approximately $20 billion.
KV said it expects the products to enter the U.S. marketplace over the next several years through 2017, subject to Food and Drug Administration approvals.
Two of the products are already filed with the FDA and a third is expected to be filed shortly.
Under terms of the agreement, Gedeon Richter will be responsible for the development, manufacturing and regulatory requirements of the products. The company will receive a share of the revenues.
More specific terms of the agreement were not disclosed.
"This agreement substantially augments our Ethex generic drug pipeline in attractive therapeutic categories," KV vice chairman and chief executive officer Marc S. Hermelin said in the release.
"Gedeon Richter has been a terrific partner as demonstrated by the international licensing of our two NDA-approved anti-infective products, Gynazole-1 and more recently Clindesse. Today's announcement extends this relationship from the branded marketplace to the generic marketplace."
KV is a specialty pharmaceutical company that develops, manufactures and markets and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The company is based in St. Louis.
Gedeon is a pharmaceutical company located in Budapest, Hungary.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.